000128185 001__ 128185
000128185 005__ 20240228135046.0
000128185 0247_ $$2doi$$a10.1158/0008-5472.CAN-13-2311
000128185 0247_ $$2pmid$$apmid:24906623
000128185 0247_ $$2ISSN$$a0008-5472
000128185 0247_ $$2ISSN$$a0099-7013
000128185 0247_ $$2ISSN$$a0099-7374
000128185 0247_ $$2ISSN$$a1538-7445
000128185 0247_ $$2altmetric$$aaltmetric:2517748
000128185 037__ $$aDKFZ-2017-04203
000128185 041__ $$aeng
000128185 082__ $$a610
000128185 1001_ $$0P:(DE-He78)cc84101e4a6f5a7a41c9012f423dbd0f$$aRunge, Anja$$b0$$eFirst author$$udkfz
000128185 245__ $$aAn inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice.
000128185 260__ $$aPhiladelphia, Pa.$$bAACR$$c2014
000128185 3367_ $$2DRIVER$$aarticle
000128185 3367_ $$2DataCite$$aOutput Types/Journal article
000128185 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521199489_1657
000128185 3367_ $$2BibTeX$$aARTICLE
000128185 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128185 3367_ $$00$$2EndNote$$aJournal Article
000128185 520__ $$aThe limited availability of experimental tumor models that faithfully mimic the progression of human tumors and their response to therapy remains a major bottleneck to the clinical translation and application of novel therapeutic principles. To address this challenge in hepatocellular carcinoma (HCC), one of the deadliest and most common cancers in the world, we developed and validated an inducible model of hepatocarcinogenesis in adult mice. Tumorigenesis was triggered by intravenous adenoviral delivery of Cre recombinase in transgenic mice expressing the hepatocyte-specific albumin promoter, a loxP-flanked stop cassette, and the SV40 large T-antigen (iAST). Cre recombinase-mediated excision of the stop cassette led to a transient viral hepatitis and resulted in multinodular tumorigenesis within 5 to 8 weeks. Tumor nodules with histologic characteristics of human HCC established a functional vasculature by cooption, remodeling, and angiogenic expansion of the preexisting sinusoidal liver vasculature with increasing signs of vascular immaturity during tumor progression. Treatment of mice with sorafenib rapidly resulted in the induction of vascular regression, inhibition of tumor growth, and enhanced overall survival. Vascular regression was characterized by loss of endothelial cells leaving behind avascular type IV collagen-positive empty sleeves with remaining pericytes. Sorafenib treatment led to transcriptional changes of Igf1, Id1, and cMet over time, which may reflect the emergence of potential escape mechanisms. Taken together, our results established the iAST model of inducible hepatocarcinogenesis as a robust and versatile preclinical model to study HCC progression and validate novel therapies.
000128185 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000128185 588__ $$aDataset connected to CrossRef, PubMed,
000128185 650_7 $$2NLM Chemicals$$aAngiogenesis Inhibitors
000128185 650_7 $$2NLM Chemicals$$aPhenylurea Compounds
000128185 650_7 $$025X51I8RD4$$2NLM Chemicals$$aNiacinamide
000128185 650_7 $$09ZOQ3TZI87$$2NLM Chemicals$$asorafenib
000128185 7001_ $$0P:(DE-HGF)0$$aHu, Junhao$$b1
000128185 7001_ $$0P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc$$aWieland, Matthias$$b2$$udkfz
000128185 7001_ $$0P:(DE-HGF)0$$aBergeest, Jan-Philip$$b3
000128185 7001_ $$0P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654$$aMogler, Carolin$$b4$$udkfz
000128185 7001_ $$0P:(DE-HGF)0$$aNeumann, André$$b5
000128185 7001_ $$aGéraud, Cyrill$$b6
000128185 7001_ $$0P:(DE-He78)554abc2af2666cc3421cc0d7f6e7b6de$$aArnold, Bernd$$b7$$udkfz
000128185 7001_ $$0P:(DE-He78)f1db1035ee9130131effb4f2f60553ae$$aRohr, Karl$$b8$$udkfz
000128185 7001_ $$0P:(DE-He78)30816ab8532422ad8d4a8af55bc0d24b$$aKomljenovic, Dorde$$b9$$udkfz
000128185 7001_ $$0P:(DE-HGF)0$$aSchirmacher, Peter$$b10
000128185 7001_ $$aGoerdt, Sergij$$b11
000128185 7001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b12$$eLast author$$udkfz
000128185 773__ $$0PERI:(DE-600)2036785-5$$a10.1158/0008-5472.CAN-13-2311$$gVol. 74, no. 15, p. 4157 - 4169$$n15$$p4157 - 4169$$tCancer research$$v74$$x1538-7445$$y2014
000128185 909CO $$ooai:inrepo02.dkfz.de:128185$$pVDB
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cc84101e4a6f5a7a41c9012f423dbd0f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)554abc2af2666cc3421cc0d7f6e7b6de$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f1db1035ee9130131effb4f2f60553ae$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)30816ab8532422ad8d4a8af55bc0d24b$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000128185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000128185 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000128185 9141_ $$y2014
000128185 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128185 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER RES : 2015
000128185 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128185 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128185 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128185 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128185 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128185 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128185 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128185 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128185 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128185 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128185 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128185 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER RES : 2015
000128185 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lVaskuläre Onkologie und Metastasierung$$x0
000128185 9201_ $$0I:(DE-He78)D050-20160331$$kD050$$lMolekulare Immunologie$$x1
000128185 9201_ $$0I:(DE-He78)B080-20160331$$kB080$$lTheoretische Bioinformatik$$x2
000128185 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lMedizinische Physik in der Radiologie$$x3
000128185 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000128185 980__ $$ajournal
000128185 980__ $$aVDB
000128185 980__ $$aI:(DE-He78)A190-20160331
000128185 980__ $$aI:(DE-He78)D050-20160331
000128185 980__ $$aI:(DE-He78)B080-20160331
000128185 980__ $$aI:(DE-He78)E020-20160331
000128185 980__ $$aI:(DE-He78)L101-20160331
000128185 980__ $$aUNRESTRICTED